- Home
- EDIT vs HUMA Comparison
EDIT vs HUMA Comparison
Compare EDIT & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDIT | HUMA |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.1M | 182.6M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | EDIT | HUMA |
|---|---|---|
| Price | $2.19 | $1.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $4.50 | ★ $10.00 |
| AVG Volume (30 Days) | 1.9M | ★ 5.4M |
| Earning Date | 03-04-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $46,383,000.00 | $1,571,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $731.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.91 | $0.91 |
| 52 Week High | $4.54 | $4.85 |
Technical Indicators
Market Signals| Indicator | EDIT | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 48.83 | 45.11 |
| Support Level | $1.92 | $0.96 |
| Resistance Level | $2.43 | $1.15 |
| Average True Range (ATR) | 0.15 | 0.09 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 51.84 | 33.20 |
Price Performance
Historical ComparisonAbout EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.